Eli Lilly and Company

BEBTELOVIMAB

Manufacturer:

Eli Lilly and Company

Bebtelovimab HCPCS:

Q0222

HCPCS Code Descriptor:

Injection, bebtelovimab, 175 mg

Category:

Q Code

Bebtelovimab NDCs:

No actively aligned NDCs found

Primary Type:

COVID-19

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Bebtelovimab CPT Codes:

Potential CPT administration codes for Bebtelovimab can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Bebtelovimab:

BEBTELOVIMAB is a COVID-19 drug manufactured by Eli Lilly and Company and administered via the Intravenous route of administration. The Q Code: Q0222 is aligned to the drug BEBTELOVIMAB.

ACCESS PRICING AND MORE BY REGISTERING

Q0222 Added Date:

February 11, 2022

Q0222 Effective Date:

February 11, 2022

Q0222 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Bebtelovimab billing and coding information.
Our team did not identify a source for Bebtelovimab patient assistance information. Please reach out to our team if you feel that this is a mistake.
BEBTELOVIMAB prescribing information can be found at the link below:
Information regarding BEBTELOVIMAB’s side effects can be found at MedlinePlus